|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Biopsy findings revealed a moderately differentiated adenocarcinoma with immunohistochemical profile supporting prostate as the primary tumor site: negative for cytokeratin-7 and cytokeratin-20 and positive for prostate-specific antigen, prostate-specific acid phosphatase, and alpha-methylacyl-CoA-racemase.
|
30832497 |
2020 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
These results were supported by human data showing that PEG10 expression is highest in NEPC and that AR-dependent gene, PSA, is negatively correlated with PEG10 in adenocarcinoma.
|
31013476 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The prognostic value of prostate-specific antigen (PSA) in NEPC and adenocarcinoma was evaluated using Cox regression and the Kaplan-Meier method.
|
31376193 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The xenografted line showed histology consistent with a poorly differentiated adenocarcinoma and stained positively for prostatic acid phosphatase (PAcP), epithelial membrane antigen (EMA) and the cytokeratin cocktail, CAM5.2, with weak staining for prostate specific antigen (PSA).
|
25560784 |
2015 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We assessed the capacity of 2 mCMV-based vectors to induce PSA-specific CD8 T-cell responses and affect the growth of PSA-expressing Transgenic Adenocarcinoma of the Mouse Prostate tumors (TRAMP-PSA).
|
22576344 |
2012 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The majority of the prostatic cancers are adenocarcinomas characterized by glandular formation and the expression of luminal differentiation markers androgen receptor (AR) and prostate-specific antigen (PSA).
|
21432867 |
2011 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy.
|
18491956 |
2008 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry revealed that CA19-9 was positive in the ductal adenocarcinoma, and prostate-specific antigen was positive in the conventional well-differentiated adenocarcinoma.
|
18036053 |
2007 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We conducted the animal experiments using athymic nude mice bearing human salivary adenocarcinoma to examine the role of NK cells in OK-PSA-induced anti-tumor immunity.
|
12530069 |
2003 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We also performed a prospective, blinded investigation to quantitate GSTP1 promoter methylation in sextant prostate biopsy specimens from 21 additional patients with elevated serum prostate-specific antigen levels, 11 of whom had histologically identified adenocarcinoma and 10 of whom had no morphologic evidence of adenocarcinoma.
|
11717336 |
2001 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Both had a high serum PSA level and biopsies revealed moderately-differentiated adenocarcinomas in both.
|
9712452 |
1998 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumors grown in nude mice revealed a poorly differentiated adenocarcinoma with positive PSA staining.
|
2195744 |
1990 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
No significant differences could be found in the PSA gene expression between BPH and CA samples.
|
1691151 |
1990 |